EP Patent

EP0782569A1 — Racemisation and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof

Assigned to Darwin Discovery Ltd · Expires 1997-07-09 · 29y expired

What this patent protects

A process for the racemisation of an optically-enriched piperidine-2-carboxanilide compound, comprises heating the compound in the presence of an alkanoic or arylalkanoic acid. A process for the asymmetric transformation of such a compound comprises heating the compound in the pr…

USPTO Abstract

A process for the racemisation of an optically-enriched piperidine-2-carboxanilide compound, comprises heating the compound in the presence of an alkanoic or arylalkanoic acid. A process for the asymmetric transformation of such a compound comprises heating the compound in the presence of an acid as defined above, a chiral acid resolving agent and an inert cosolvent.

Drugs covered by this patent

Patent Metadata

Patent number
EP0782569A1
Jurisdiction
EP
Classification
Expires
1997-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Darwin Discovery Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.